All In Biotech

NDA 017057 · Liebel-Flarsheim

Cysto-Conray Ii

Iothalamate Meglumine · Intravesical, Intravesical, Ureteral

Last checked: Nov 20, 2026Latest source record: Dec 19, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1972

Apr 17, 1972

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

1 Phase 3, 0 recruiting

FAERS reports

16

5 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

NOT FOR INTRAVASCULAR ADMINISTRATION NOT FOR INTRATHECAL USE

What it is approved for

From the label in effect Dec 31, 2020.

INDICATIONS AND USAGE Cysto-Conray II is indicated for use in retrograde cystography and cystourethrography.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 17, 1972 Original approval · Type 3 - New Dosage Form
2 products under this application
  • CYSTO-CONRAY II · IOTHALAMATE MEGLUMINE 17.2% · SOLUTION, INTRAVESICAL · Prescription
  • CYSTO-CONRAY · IOTHALAMATE MEGLUMINE 43% · Solution, Intravesical, Ureteral · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Iothalamate Meglumine" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • incorrect route of drug administration8
  • wrong drug administered4
  • anaphylactoid reaction2
  • no adverse event2
  • agranulocytosis1
  • anaphylactic reaction1
  • angioedema1
  • cough1
  • drug ineffective1
  • expired product administered1
  • fixed eruption1
  • hypersensitivity1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20112
20121
20134
20142
20151
20162
20181
20251
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Cysto-Conray Ii* (Iothalamate Meglumine*) · HCPCS Q9958

2024 spending

$9K

Beneficiaries

691

768 claims

Per beneficiary

$14

2024 ASP limit $0.08 per unit

View as table
YearSpending
2020$12,981
2021$13,140
2022$10,356
2023$10,083
2024$9,453

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Liebel-Flarsheim · Also marketed as Cysto-Conray

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.